A case-control study of non-AIDS-defining cancers in a prospective cohort of HIV-infected patients

Arrondo, Francisco Rodríguez; Wichmann, Miguel Ángel von; Camino, Xabier; Goenaga, Miguel Ángel; Ibarguren, Maialen; Azcune, Harkaitz; Bustinduy, María Jesús; Ferrero, Oscar; Muñoz, Josefa; Ibarra, Sofía; Aguirrebengoa, Koldo; Goicoetxea, Josune; Bereciartúa, Elena; Montejo, Miguel; García, M.Á. Bonillo; Martínez, Eduardo; Portu, Joseba; Metola, Luís; Silvariño, Rafael; Sarasqueta, Cristina; Arrizabalaga, J; Iribarren, José Antonio; SEINORTE, Grupo

doi:10.1016/j.medcle.2018.02.001

Cited by 7 publications

(11 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The most common cancers associated with smoking among PWH include lung (incidence rate [IR] 91-175 per 100,000), head and neck (IR 80), esophageal (IR 12-21), anal (IR 76-147), and cervical cancers (IR 21 -506) [43]. Cancer of lung and head and neck, combined, are particularly associated with smoking in PWH, with over 8.5-fold higher risk compared to non-smoking PWH [44]. Excluding lung cancer, ever smoking remains associated with 36% increased risk for NADCs, with an attributable risk of 24% [45].…”

Section: Smokingmentioning

confidence: 99%

Contribution of Behavioral Health Factors to Non-AIDS-Related Comorbidities: an Updated Review

et al. 2020

View full text Add to dashboard Cite

Purpose of review:We summarize recent literature on the contribution of substance use and depression to non-AIDS-related comorbidities. Discussion of recent randomized clinical trials and implementation research to curtail risk attributed to each behavioral health issue is provided.Recent Findings: Smoking, unhealthy alcohol use, opioid use, and depression are common among PWH and individually contribute to increased risk for non-AIDS-related comorbidities. The concurrence of these conditions is notable, yet understudied, and provides opportunity for linked-screening and potential treatment of more than one behavioral health factor. Current results from randomized clinical trials are inconsistent. Investigating interventions to reduce the impact of these behavioral health conditions with a focus on implementation into clinical care is important.Terms of use and reuse: academic research for non-commercial purposes, see here for full terms. http://www.springer.com/gb/openaccess/authors-rights/aam-terms-v1

show abstract

Section: Smokingmentioning

confidence: 99%

Contribution of Behavioral Health Factors to Non-AIDS-Related Comorbidities: an Updated Review

et al. 2020

View full text Add to dashboard Cite

show abstract

“…However, there has been a parallel increase in the incidence of non-AIDS cancers 1 – 7 , which constitute a heterogeneous group of neoplasms including, among others, cancers of the lung, liver, anus, head, neck, skin, and Hodgkin’s lymphoma. A low CD4 count at diagnosis, the duration of previous ART treatment, smoking, and age at diagnosis have been described as predictors of the appearance of non-AIDS cancers 5 . Recent estimations suggest that by 2030 lung, prostate, liver, and anus cancers will be the most frequent cancers in the USA in HIV-infected individuals 8 .…”

Section: Introductionmentioning

confidence: 99%

Prevalence of HPV-DNA and E6 mRNA in lung cancer of HIV-infected patients

Sirera

Videla

Saludes

et al. 2022

Sci Rep

View full text Add to dashboard Cite

HIV-infected individuals could be at a greater risk for developing lung cancer than the general population due to the higher prevalence in the former of human papillomavirus (HPV) in the oral cavity and higher smoking rates. Our aim was to assess HPV prevalence and E6 viral oncogene transcription in lung cancer samples from HIV-infected individuals. This was a single-center, retrospective study of a cohort of HIV-1-infected patients diagnosed with and treated for lung cancer. Pathological lung samples archived as smears or formalin-fixed paraffin-embedded blocks were subjected to HPV genotyping, detection of human p16 protein and assessment for HPV E6 mRNA expression. Lung cancer samples from 41 patients were studied, including squamous cell carcinoma (32%), adenocarcinoma (34%), non-small cell cancer (27%), and small cell cancer (7%). HPV DNA was detected in 23 out of 41 (56%, 95% CI 41–70%) of samples and high-risk (HR)-HPV types were detected in 16 out of 41 (39%, 95% CI 26–54%), HPV-16 being the most prevalent [13/16 (81.3%, 95% CI 57.0–93%]. In samples with sufficient material left: expression of p16 was detected in 3 out of 10 (30%) of HR-HPV DNA-positive tumors and in 3 out of 7 (43%) of the negative ones; and E6 mRNA was detected in 2 out of 10 (20%) of HPV-16-positive samples (squamous lung cancers). These two patients had a background of a previous HPV-related neoplasia and smoking. HR-HPV DNA detection was prevalent in lung cancers in HIV-infected patients. However, viral oncogene expression was limited to patients with previous HPV-related cancers.

show abstract

“…Oral lesions as well as manifestations of lymphomas associated with HIV infection are less common but should be considered, especially in patients with advanced HIV infection who are at higher risk of developing these conditions [10]. In these patients, the risk of developing non-Hodgkin's lymphoma is 100-200 times higher compared to that in the general population [11], and this malignancy ranks second, after Kaposi's sarcoma [12].…”

Section: Introductionmentioning

confidence: 99%

A Rare Case of Plasmablastic Lymphoma in a Patient with HIV and SARS-CoV-2 Infections

et al. 2022

View full text Add to dashboard Cite

Lesions commonly associated with HIV infection include oral candidiasis, herpes simplex infection, oral Kaposi’s sarcoma, hairy leukoplakia, periodontal diseases (linear gingival erythema and necrotizing ulcerative periodontitis), xerostomia, human papillomavirus-associated warts, aphthous ulcers, non-Hodgkin’s lymphoma, histoplasmosis, carcinoma, exfoliative cheilitis, and HIV salivary gland disease. Non-Hodgkin’s lymphoma (NHL) is the most common cancer in people living with HIV (PLWH), and the incidence is increased for aggressive B-cell NHL. Plasmablastic lymphoma (PbL) is a rare and aggressive B-cell malignancy that is often unresponsive to chemotherapy and usually has a poor prognosis. We hereby present the case of a patient with a recent history of COVID-19 infection who was diagnosed with HIV and NHL, with manifestations in the oral cavity and a favorable evolution after the introduction of antiviral therapy, specific chemotherapy, and radiotherapy. Dental expertise is necessary for the appropriate management of oral manifestations of HIV infection or AIDS, and lymphoma should be included in the differential diagnosis of any oral lesions.

show abstract

A case-control study of non-AIDS-defining cancers in a prospective cohort of HIV-infected patients

Cited by 7 publications

References 30 publications

Contribution of Behavioral Health Factors to Non-AIDS-Related Comorbidities: an Updated Review

Contribution of Behavioral Health Factors to Non-AIDS-Related Comorbidities: an Updated Review

Prevalence of HPV-DNA and E6 mRNA in lung cancer of HIV-infected patients

A Rare Case of Plasmablastic Lymphoma in a Patient with HIV and SARS-CoV-2 Infections

Contact Info

Product

Resources

About